# Study Evaluating Rapamune® Maintenance Regimen

> **NCT00478608** · PHASE3 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 79 (actual)

## Conditions studied

- Renal Transplant

## Interventions

- **DRUG:** Sirolimus (Rapamune®)

## Key facts

- **NCT ID:** NCT00478608
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2010-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00478608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00478608, "Study Evaluating Rapamune® Maintenance Regimen". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00478608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*